SUTENT (sunitinib malate) is used for the treatment of patients with renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST)

SUTENT is a kinase inhibitor indicated for the treatment of • Gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. • Advanced renal cell carcinoma (RCC). • Progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced or metastatic disease.

SUTENT (sunitinib malate) suppliers in India. Indian Pharma Network (IPN) New Delhi, INDIA.

IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.

For procurement cost of SUTENT (sunitinib malate) brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the SUTENT (sunitinib malate) medicine cost price in India.

The order for SUTENT (sunitinib malate) will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Sunitinib (marketed as Sutent by Pfizer, and previously known as SU11248) is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications

SUTENT® (sunitinib malate) capsules, oral Initial U.S. Approval: 2006

Generic Name: sunitinib malate

SUTENT (Sunitib)

GET IN TOUCH
with Indian Pharma Network

Indian Pharma Network, Delhi provides access to SUTENT (Sunitib) on the Named Patient Import basis in India.

Indian Pharma Network (IPN), Delhi. India

IPN, Delhi is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India. IPN, New Delhi helps patient, providing solutions on how to get access of anti cancer medicines which is not available in India.

BRANCH OFFICE : NEW DELHI | BENGALURU | KOLKATA | LUCKNOW | JODHPUR

Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Saudi Arabia | South Africa

Indian Pharma Network

60/4 1st Floor, T&T Building, Indian Oil Complex,
Yusuf Sarai, New Delhi, Delhi 110016

Mobile / WhatsApp / Phone

M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398

Free Customer Support

info@indianpharmanetwork.co.in
urgent@indianpharmanetwork.co.in

SUTENT (sunitinib malate) suppliers in India

IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand SUTENT (sunitinib malate) on prescription and Import License in Patient's Name only.

For overseas patients, SUTENT (sunitinib malate) can be made available in Send your enquiry to find SUTENT (sunitinib malate) in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.

News / Update for SUTENT (sunitinib malate).

For SUTENT (sunitinib malate) Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details

FDA expands approval of Sutent to reduce the risk of kidney cancer returning For More Details

Immunotherapy Brings More Options for Frontline RCC Treatment For More Details

Get Access To FDA Approved Drugs.

Indian Pharma Network (IPN), Delhi India is a leading Pharmaceutical Distributor / Supplier / Exporter / Importer of Anti-Cancer Medicines, used in for the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy treatment. Brand Name "SUTENT (sunitinib malate) capsules" or Generic Name "Sunitinib malate capsules" can be imported for personal use under "patient name basis" treatment in Delhi, Noida, Gurgaon, Mumbai, Chennai, Kolkatta, Bangalore, Jaipur, Chandigarh India. Contact us at urgent@indianpharmanetwork.co.in or call/WhatsApp at +91 9891296838 / 9811747774 to get access as per norms.